Videos

Joseph M. Scandura, MD, PhD, provides an overview on the research of pelabresib which will be discussed at the 2022 American Society of Hematology Annual Meeting.

Charles J. Schneider, MD, FACP, discusses some of the ongoing research examining patients with anal cell carcinoma.

Ghassan K. Abou-Alfa, MD, discusses the LEAP-002 study of pembrolizumab plus lenvatinib vs lenvatinib alone in patients with unresectable hepatocellular carcinoma.

Susana Banerjee, MBBS, PhD, discusses the updated results of the MEDIOLA trial of patients with ovarian cancer presented at the 2022 European Society for Medical Oncology Congress.

Maryam Lustberg, MD, MPH, explains how the HER2 low session during the 2022 San Antonio Breast Cancer Symposium.

Thomas James Kipps, MD, PhD, discusses the role of later generation and newer generation burton tyrosine kinase inhibitors in patients with chronic lymphocytic leukemia.

Nurse Practitioner Lauren Welch and Dr Michelle Shiller explain if and when they would offer repeat liquid or tissue biopsies to a patient with mNSCLC, and discuss how often patients request “serial biopsies” for detecting treatment response and/or disease progression.

A key opinion leader muses on the treatments she would consider for a patient with mNSCLC, an EGFR exon 20 mutation, and brain metastases.

Shirish M. Gadgeel, MD, MBBS, discusses the results of the KRYSTAL-1 trial trial of adagrasib in patients with KRAS-positive non–small cell lung cancer.

David O’Malley, MD, discusses updated results from the KEYNOTE-158 trial of pembrolizumab in patients with advanced endometrial cancer.

Jason Westin, MD, MS, FACP, discusses recent developments in novel agents to treat and target aggressive lymphomas.

Erica Stringer-Reasor, MD, discusses the leptomeningeal metastases in patients with breast cancer and an FDA-approved targeted therapy/chemotherapy combination that is being studied as a treatment.

Alexey Danilov, MD, PhD, provides an overview on the recent updates and research in the chronic lymphocytic leukemia space.

Tapan Kadia, MD, discusses potential improvements to lower intensity therapy for less fit patients with acute myeloid leukemia.

Edward B. Garon, MD, MS, provides an overview of the phase 3 CANOPY-A study.

Closing out their discussion on bispecific antibody therapies, Matthew Matasar, MD and Laurie Sehn, MD, consider ongoing clinical trials and real-world use of these novel agents.

Experts Matthew Matasar, MD and Laurie Sehn, MD, nuance the adverse event profiles of bispecific antibody therapies and consider how these will help inform treatment decisionmaking.

Expert perspectives on the advent of bispecific antibody therapy in relapsed/refractory follicular lymphoma, centered on data and experience with several novel agents.

Shared insight on the development and use of CAR T-cell therapy in patients with multiply relapsed follicular lymphoma.

Switching to the paradigm of multiply relapsed follicular lymphoma, expert participants discuss the rationale behind and use of PI3k- and EZH2- targeted therapies.

Matthew Matasar, MD and Laurie Sehn, MD, share insight on available therapies for relapsed or refractory follicular lymphoma and reflect on factors that help in treatment selection.

Centering discussion on both symptomatic and asymptomatic disease, expert participants highlight cornerstone frontline therapies in follicular lymphoma.

A brief review of the role that PET imaging plays in staging follicular lymphoma and how it may inform treatment decisions.

Key opinion leaders in the management of follicular lymphoma share their perspective on risk stratification and staging strategies to inform treatment decisionmaking.

Opening their discussion on follicular lymphoma, experts Matthew Matasar, MD and Laurie Sehn, MD, reflect on its indolent nature as a subset of non-Hodgkin lymphoma.

Closing out their discussion on the management of myeloproliferative neoplasms, Rami S. Komrokji, MD, and Pankit Vachhani, MD, look toward the future treatment paradigm.

Sagar Lonial, MD, FACP, provides a look at an upcoming Virtual Tumor Board program on BCMA-directed therapies in relapsed/refractory multiple myeloma treatment.

Lajos Pusztai, MD, DPhil, discusses recent data from the phase 3 KEYNOTE-522 trial of patients with triple-negative breast cancer.

Fred Saad, MD, FRSC, discusses the findings of a biomarker analysis of the PROpel trial in patients with metastatic castration-resistant prostate cancer.

The panel reviews the first- and second-line treatment options for the patient in the presented case, before and after knowing her molecular testing results.